BREAKING
Earnings Summary: Zymeworks (ZYME) Q4 FY25 net loss widens 4 hours ago Earnings Summary: A snapshot of Smith+Nephew’s (SNN) Q4 2025 report 5 hours ago Earnings Summary: Norwegian Cruise Line (NCLH) Q4 FY25 revenue rises 6% 6 hours ago Earnings Summary: Highlights of Calumet’s (CLMT) Q4 2025 earnings report 3 days ago Zoom Communications Q4 2025 Earnings Results 4 days ago Agilent Q1 Revenue Rises 7%, Net Income Declines 4 days ago Synopsys Q1 2026 Earnings Results 4 days ago Key highlights from J.M. Smucker’s (SJM) Q3 2026 earnings results 4 days ago Hormel Foods (HRL) Q1 2026 Earnings: Key financials and quarterly highlights 4 days ago Key metrics from Lowe’s (LOW) Q4 2025 earnings results 5 days ago Earnings Summary: Zymeworks (ZYME) Q4 FY25 net loss widens 4 hours ago Earnings Summary: A snapshot of Smith+Nephew’s (SNN) Q4 2025 report 5 hours ago Earnings Summary: Norwegian Cruise Line (NCLH) Q4 FY25 revenue rises 6% 6 hours ago Earnings Summary: Highlights of Calumet’s (CLMT) Q4 2025 earnings report 3 days ago Zoom Communications Q4 2025 Earnings Results 4 days ago Agilent Q1 Revenue Rises 7%, Net Income Declines 4 days ago Synopsys Q1 2026 Earnings Results 4 days ago Key highlights from J.M. Smucker’s (SJM) Q3 2026 earnings results 4 days ago Hormel Foods (HRL) Q1 2026 Earnings: Key financials and quarterly highlights 4 days ago Key metrics from Lowe’s (LOW) Q4 2025 earnings results 5 days ago
ADVERTISEMENT
Market News

Earnings: Array BioPharma reports upbeat Q3 results

Array BioPharma (NASDAQ: ARRY) reported a narrower-than-expected loss in the third quarter of 2019, sending its shares up 0.5% during pre-market trading on Tuesday. The company reported a loss of 17 cents per share, compared to 21 cents expected by Wall Street. Revenues for the quarter fell to $64.7 million, primarily due to the recognition […]

May 7, 2019 1 min read
“

Array BioPharma (NASDAQ: ARRY) reported a narrower-than-expected loss in the third quarter of 2019, sending its shares up 0.5% during pre-market trading on Tuesday. The company reported a loss of 17 cents per share, compared to 21 cents expected by Wall Street. Revenues for the quarter fell to $64.7 million, primarily due to the recognition […]

· May 7, 2019

Array BioPharma (NASDAQ: ARRY) reported a narrower-than-expected loss in the third quarter of 2019, sending its shares up 0.5% during pre-market trading on Tuesday. The company reported a loss of 17 cents per share, compared to 21 cents expected by Wall Street.

Revenues for the quarter fell to $64.7 million, primarily due to the recognition of the Vitrakvi milestones in the prior quarter. But the top line was still higher than the street view of $51.5 million.

Image for representation (Photo by Drew Hays on Unsplash)

ARRY shares have gained 55% so far this year and 65% in the year-to-date period.

CEO Ron Squarer said, “U.S. demand for BRAFTOVI + MEKTOVI for patients with BRAF-mutant metastatic melanoma continues to be strong with over $35 million in net product sales during the third commercial quarter.”

READ: THE QUESTION EVERY POT INVESTOR ASKS HIMSELF – AURORA CANNABIS OR HEXO?

ADVERTISEMENT

Net Product Sales for BRAFTOVI + MEKTOVI for the third quarter of fiscal 2019 were $35.1 million, compared to $22.7 million for the second quarter of fiscal 2019.

The Boulder, Colorado-based biotechnology firm has partnered with Bristol-Myers Squibb (BMY), Merck (MRK) and Pfizer (PFE) to study numerous cancer drug combinations.

 

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

ADVERTISEMENT

Related Articles